Technical Analysis for MRSN - Mersana Therapeutics, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Down | Down |
| Historical MRSN trend table... | |||
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| Bullish Engulfing | Bullish | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| MACD Bearish Signal Line Cross | Bearish | 5.62% | |
| Calm After Storm | Range Contraction | 5.62% | |
| Wide Bands | Range Expansion | 5.62% | |
| Down 3 Days in a Row | Weakness | 5.62% | |
| Down 4 Days in a Row | Weakness | 5.62% | |
| Down 5 Days in a Row | Weakness | 5.62% | |
| Fell Below 20 DMA | Bearish | 2.50% | |
| Fell Below 50 DMA | Bearish | 2.50% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time | |
|---|---|---|
| Rose Above Previous Day's High | 2 days ago | |
| Up 5% | 2 days ago | |
| 60 Minute Opening Range Breakout | 2 days ago | |
| Up 3% | 2 days ago | |
| Up 2% | 2 days ago |
Get a Trading Sidekick!
Let us help you stay on top of your investments. We will alert you to important technical developments on your
portfolio & watchlist.
Configure default chart indicators
Basic chart:
- Earnings date: 05/08/2020
- Sector: Healthcare
- Industry: Biotechnology
Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.
Medicine Biotechnology Cancer Immunology Cancers Monoclonal Antibodies Chemotherapy Antibody Drug Conjugates Adc Synaffix
Medicine Biotechnology Cancer Immunology Cancers Monoclonal Antibodies Chemotherapy Antibody Drug Conjugates Adc Synaffix
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 26.64 |
| 52 Week Low | 1.32 |
| Average Volume | 959,197 |
| 200-Day Moving Average | 12.98 |
| 50-Day Moving Average | 19.85 |
| 20-Day Moving Average | 19.93 |
| 10-Day Moving Average | 21.85 |
| Average True Range | 2.00 |
| ADX | 20.76 |
| +DI | 21.67 |
| -DI | 19.17 |
| Chandelier Exit (Long, 3 ATRs ) | 20.65 |
| Chandelier Exit (Short, 3 ATRs ) | 21.44 |
| Upper Bollinger Band | 25.15 |
| Lower Bollinger Band | 14.72 |
| Percent B (%b) | 0.45 |
| BandWidth | 52.34 |
| MACD Line | 0.29 |
| MACD Signal Line | 0.49 |
| MACD Histogram | -0.2011 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 21.78 | ||||
| Resistance 3 (R3) | 21.57 | 20.59 | 21.39 | ||
| Resistance 2 (R2) | 20.59 | 20.00 | 20.70 | 21.26 | |
| Resistance 1 (R1) | 20.02 | 19.63 | 20.31 | 20.23 | 21.13 |
| Pivot Point | 19.04 | 19.04 | 19.18 | 19.15 | 19.04 |
| Support 1 (S1) | 18.47 | 18.45 | 18.76 | 18.68 | 17.78 |
| Support 2 (S2) | 17.49 | 18.08 | 17.60 | 17.65 | |
| Support 3 (S3) | 16.92 | 17.49 | 17.52 | ||
| Support 4 (S4) | 17.13 |
